-
公开(公告)号：US20190382423A1
公开(公告)日：2019-12-19
申请号：US15750480
申请日：2017-11-20
Inventor： Mokkapati Umamaheshwar PRASAD , Anjul KUMAR , Shishupal SINGH , Dharam VIR
IPC: C07F9/50
Abstract: The present invention relates to an improved process for the preparation of tetrofosmin or acid addition salt thereof. The present invention also relates to the process for the preparation of tetrofosmin disulfosalicylate salt. Further the present invention also provides the polymorphic form J of disulfosalicylate salt of tetrofosmin.
-
2.发明申请PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT 审中-公开制备线性稳定的结晶形式的方法，大量无残留溶剂公开(公告)号：US20170066728A1
公开(公告)日：2017-03-09
申请号：US15356374
申请日：2016-11-18
Applicant: Jubilant Life Sciences Limited
Inventor： Sujay BISWAS , Atulya Kumar PANDA , Ashish Kumar GUPTA , Shishupal SINGH , Praveen TIWARI , Dharam VIR , Saji THOMAS
IPC: C07D263/24
CPC classification number: C07D263/24 , C07B2200/07 , C07B2200/13 , C07D263/20
Abstract: The invention relates to a process of preparation of enantiomerically pure Linezolid Form-I comprising converting a substantially enantiomerically pure linezolid hydroxide compound of formula II to Linezolid Form I compound of formula I.
Abstract translation: 本发明涉及相对于其S-异构体，具有大于约99.9％的R-异构体含量的基本上纯的线状固体氢氧化物。 本发明的另一方面提供了环境湿度条件，这对于对映体纯的利奈唑烷氢氧化物是至关重要的。 得到的基本上对映异构体纯的式-II的线状固体氢氧化物化合物随后可以转化为相对于R-异构体的S-异构体含量大于99.9％的式-I的利奈唑胺化合物。 此外，本发明提供了制备对映异构体纯利奈唑胺Form-1的改进方法，其中相对于任何其他已知的多晶型形式的利奈唑胺而言，纯度大于99.9％的利奈唑胺形式I。 获得的对映体纯利奈唑胺形式I可以随后转化成其他已知的多晶型物利奈唑胺。 本发明还提供了稳定且基本上无溶剂的利奈唑胺形式I的晶体。
-
公开(公告)号：US20170015620A1
公开(公告)日：2017-01-19
申请号：US15124003
申请日：2015-03-17
Applicant: Jubilant Life Sciences Limited
Inventor： Sujay BISWAS , Vikas BANSAL , Rohit CHAKRAVARTY , Mokkapati Umamaheshwar PRASAD , Mukesh MASAND , Dharam VIR
IPC: C07C249/12 , C07B57/00 , C07C249/14
CPC classification number: C07C249/12 , C07B57/00 , C07B2200/07 , C07C249/04 , C07C249/14 , C07C251/38
Abstract: The present invention provides an improved process for the preparation of exametazime, which is used as ligand in preparation of technetium-99m complex.
Abstract translation: 本发明提供了一种改进的前药制备方法，其用作制备锝-99m络合物的配体。 式（I）
-
-
Search Results
3
records
(took 0.031 seconds)
